Cover Image
市場調查報告書

雷葛氏症候群:開發平台分析

Lennox-Gastaut Syndrome - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 321924
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
雷葛氏症候群:開發平台分析 Lennox-Gastaut Syndrome - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 60 Pages
簡介

兒童癲癇症──雷葛氏症候群(LGS)的特徵是頻頻發生嚴重發作。原因有皮質形成異常、先天性感染症、腦中風、精神性外傷、出生時缺氧、腦炎及髓膜炎等中樞神經系統感染症,或是遺傳性障礙等。治療方法有使用抗癲癇藥和飲食療法,手術。

本報告提供雷葛氏症候群的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

雷葛氏症候群概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

研究中的產品:各大學/研究機關

開發治療藥的企業

  • Eisai
  • GW Pharmaceuticals plc
  • INSYS Therapeutics, Inc.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最新的開發中產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8153IDB

Summary

Global Markets Direct's, 'Lennox-Gastaut Syndrome - Pipeline Review, H1 2016', provides an overview of the Lennox-Gastaut Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lennox-Gastaut Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lennox-Gastaut Syndrome
  • The report reviews pipeline therapeutics for Lennox-Gastaut Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Lennox-Gastaut Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Lennox-Gastaut Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Lennox-Gastaut Syndrome

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lennox-Gastaut Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lennox-Gastaut Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lennox-Gastaut Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Lennox-Gastaut Syndrome - Overview
    • Pipeline Products for Lennox-Gastaut Syndrome - Comparative Analysis
  • Lennox-Gastaut Syndrome - Therapeutics under Development by Companies
  • Lennox-Gastaut Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Lennox-Gastaut Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Lennox-Gastaut Syndrome - Products under Development by Companies
  • Lennox-Gastaut Syndrome - Products under Investigation by Universities/Institutes
  • Lennox-Gastaut Syndrome - Companies Involved in Therapeutics Development
    • Eisai Co., Ltd.
    • GW Pharmaceuticals Plc
    • INSYS Therapeutics, Inc.
  • Lennox-Gastaut Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NRP-2945 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • perampanel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lennox-Gastaut Syndrome - Recent Pipeline Updates
  • Lennox-Gastaut Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals
      • Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy
      • Jun 11, 2015: GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study of Epidiolex in Lennox-Gastaut Syndrome
      • May 11, 2015: GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex (CBD) in Lennox-Gastaut Syndrome
      • Apr 23, 2015: Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients
      • Jan 12, 2015: Insys Therapeutics To Initiate Phase III study For An Epileptic Drug
      • Dec 05, 2014: Eisai Presents New Data on Rufinamide at the 68th Annual American Epilepsy Society Meeting
      • Oct 15, 2014: U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome
      • Jun 25, 2014: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome
      • May 07, 2014: GW Pharmaceuticals Receives Investigational New Drug From FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lennox-Gastaut Syndrome, H1 2016
  • Number of Products under Development for Lennox-Gastaut Syndrome - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Lennox-Gastaut Syndrome - Pipeline by Eisai Co., Ltd., H1 2016
  • Lennox-Gastaut Syndrome - Pipeline by GW Pharmaceuticals Plc, H1 2016
  • Lennox-Gastaut Syndrome - Pipeline by INSYS Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Lennox-Gastaut Syndrome Therapeutics - Recent Pipeline Updates, H1 2016

List of Figures

  • Number of Products under Development for Lennox-Gastaut Syndrome, H1 2016
  • Number of Products under Development for Lennox-Gastaut Syndrome - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top